Table 1.
Seroprevalence of HBsAg and HIV at First Blood Donation, National Blood Transfusion Center, Abidjan, Côte d’Ivoire 1992–2012
| Variables | 1992–1994 | 1995–1997 | 1998–2000 | 2001–2003 | 2004–2006 | 2007–2009 | 2010–2012 | P* |
|---|---|---|---|---|---|---|---|---|
| HBsAg | ||||||||
| Total screened†, N | 24 067 | 26 806 | 40 544 | 58 062 | 79 460 | 96 676 | 91 962 | NS |
| HBsAg positive†, N | 2589 | 2979 | 4400 | 6360 | 9094 | 11 300 | 10 235 | |
| Seroprevalence, % | 10.8 | 11.1 | 10.9 | 11.0 | 11.4 | 11.7 | 11.1 | |
| (95% CI) | (10.4–11.1) | (10.6–11.6) | (10.5–11.2) | (10.6–11.3) | (11.2–11.7) | (11.4–11.9) | (10.9–11.4) | |
| HIV | ||||||||
| Total screened, N | 24 700 | 27 196 | 40 816 | 58 418 | 80 031 | 98 232 | 92 926 | <.0001 |
| HIV positive, N | 1742 | 1423 | 1711 | 1577 | 1974 | 1182 | 1001 | |
| Seroprevalence, % | 7.1 | 5.2 | 4.2 | 2.7 | 2.5 | 1.2 | 1.1 | |
| (95% CI) | (6.7–7.4) | (5.0–5.5) | (4.0–4.4) | (2.6–2.8) | (2.4–2.6) | (1.1–1.3) | (1.0–1.1) | |
Abbreviations: CI, confidence interval; HBsAg, hepatitis B surface antigen; HIV, human immunodeficiency virus; N, number of individuals; NS, not significant.
*Significance for linear trend determined using a Pearson’s χ2 test.
†Over the entire 1992–2012 period, HBsAg testing results were available in the database for 417577 individuals, and HIV testing results were available for 422319 individuals. Therefore, 1.12% of the 422319 individuals with available HIV testing results had missing data on HBsAg testing.